News | February 02, 2022
Panacea Biotec sells its domestic formulations business to Mankind Pharma
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
Domestic business was up 41.9% YoY and 27.7% QoQ
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
She brings extensive expertise in managing global and domestic procurement operations
Deployment aims to improve serialization efficiency by 45% and enhance regulatory compliance across global export markets
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Doshi has established a strong track record in driving quality assurance, regulatory compliance, and formulation excellence across complex pharmaceutical operations
Subscribe To Our Newsletter & Stay Updated
